Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a ...

Core Insights - The drug discovery process is inefficient, requiring an average of 2,500 compounds and over four years to find one candidate for clinical trials [2][4] - Artificial intelligence (AI) is transforming drug discovery by analyzing large datasets and speeding up the identification of promising compounds [3] Company Summaries Recursion Pharmaceuticals - Recursion Pharmaceuticals has improved the drug discovery process, averaging 330 compounds synthesized in 17 months compared to the industry average [4] - The company utilizes a drug development operating system that integrates robotic labs, large biological datasets, and AI models, with proprietary datasets valued at $213 million from Roche and Genentech [5] - For full-year 2025, Recursion's revenue is projected at $74.7 million, with five clinical programs in progress and a cash runway extending into 2028 [6] - The company has demonstrated clinical proof-of-concept with a 43% median reduction in polyp burden for Familial Adenomatous Polyposis patients [6] Tempus AI - Tempus AI has developed a vast library of clinical and molecular data to enhance precision medicine, focusing on oncology, diagnostics, and genomics [8] - The company reported trailing revenue of $1.27 billion, growing approximately 30% annually, with a strong data engine driven by diagnostics [9] - Tempus is currently unprofitable with a net loss of $245 million, but analysts project nearly 30% annual revenue growth over the next three years [12] Industry Context - The healthcare industry in the U.S. is valued at $4.7 trillion, and advancements in AI could significantly change drug discovery and disease diagnosis [13] - Both Recursion Pharmaceuticals and Tempus AI are positioned to become integral parts of the evolving healthcare infrastructure [13][14]

Company Overview - The company has undergone significant changes in the last 12 to 24 months, particularly following a merger with Exscientia [1] - The current CFO and President, Ben Taylor, previously held roles as CFO and Chief Strategy Officer at Exscientia for over four years before the merger [2] Industry Insights - The transition into AI-based drug discovery was influenced by the realization that decision-making in the industry often relies on sparse data, leading to guesswork among professionals [3] - The company aims to improve data utilization in drug discovery to enhance decision-making processes [3]

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $3.37, with a daily increase of +1.51%, outperforming the S&P 500's loss of 0.28% [1] - Over the past month, shares of Recursion Pharmaceuticals have decreased by 5.95%, which is better than the Medical sector's decline of 7.53% but worse than the S&P 500's loss of 3.59% [1] Earnings Projections - The company is expected to report earnings of -$0.27 per share, indicating a year-over-year growth of 46% [2] - Revenue is projected to be $20.73 million, reflecting a 40.65% increase from the same quarter last year [2] - For the full year, earnings are estimated at -$0.93 per share and revenue at $90.52 million, representing increases of +35.42% and +21.21% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Recursion Pharmaceuticals are important as they reflect short-term business trends [4] - Upward revisions in estimates indicate analysts' positive outlook on the company's operations and profit generation capabilities [4] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), shows that Recursion Pharmaceuticals currently holds a Zacks Rank of 3 (Hold) [6] - Over the past month, the Zacks Consensus EPS estimate for the company has increased by 9.98% [6] - The Medical - Biomedical and Genetics industry, which includes Recursion Pharmaceuticals, has a Zacks Industry Rank of 142, placing it in the bottom 43% of over 250 industries [7]

Company Overview - Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company focused on accelerating drug discovery through automation, data science, and AI [1] - The company develops treatments for genetic, infectious, and cancer-related diseases [1] Market Sentiment - The stock has been described as "horrendous" by Jim Cramer, indicating a significant decline in performance [1] - Cramer expressed disappointment regarding the stock's performance, particularly in light of Cathie Wood's investment, suggesting it has not met expectations [1] Investment Perspective - There is acknowledgment of RXRX's potential as an investment, but it is noted that other AI stocks may offer greater upside potential with less downside risk [2] - The company is categorized as speculative, indicating a high-risk investment profile [1]

Recursion Pharmaceuticals Conference Call Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Event**: 2026 Conference held on March 09, 2026 Key Points Strategic Focus - Recursion is concentrating on three strategic areas: 1. Doubling down on proof points 2. Surgical investments in the platform 3. Pairing ambition with discipline [6][8] - The company is making rapid go-no-go decisions across its pipeline, emphasizing data-driven decision-making [6][7]. Pipeline and Portfolio Management - Recursion is synthesizing approximately 90% fewer compounds to reach advanced candidates compared to industry standards, achieving this in about half the time [7]. - The company has seven internal programs advancing and is committed to transparency in its decision-making process [9][10]. - For 2026, Recursion expects a gross burn of less than $390 million, excluding inflows from partnerships [12][13]. Partnership Dynamics - Recursion has crossed over half a billion in upfront and milestone payments from partnerships, including significant contributions from Roche and Sanofi [18][21]. - The company has a potential of $343 million in milestones per Sanofi program, with $193 million being pre-commercial [24]. - Recursion's partnerships are structured to cover direct costs upfront, allowing for efficient capital allocation [23]. Financial Management - Recursion has reduced pro forma expenses by 35%, aiming for operational excellence [27]. - The company is focused on maintaining a disciplined approach to capital allocation, with a dynamic business model that allows for quick pivots based on pipeline results [58]. Data Strategy - Recursion emphasizes the importance of proprietary data, holding 40 petabytes of data that enhances its drug discovery capabilities [29][39]. - The company is actively seeking partnerships to enhance its data assets, recognizing that no single provider has all necessary data [64]. Talent Acquisition and Management - The company faces challenges in recruiting talent that is proficient in both AI and drug discovery [52]. - Recursion aims to create a culture that values both scientific and AI expertise, which is crucial for innovation [55]. Market Dynamics - The drug discovery market is still largely untapped, with only about 3% of the genome having an approved drug [77]. - Recursion believes that the industry’s high failure rate is due to insufficient data and predictive models [78]. Future Outlook - The company is optimistic about its ability to innovate and leverage its data for better drug discovery outcomes [80]. - Recursion is committed to building a robust pipeline and maintaining flexibility in its capital strategy to adapt to market conditions [58]. Additional Insights - The integration of AI in drug discovery is seen as a significant advantage, allowing Recursion to simulate more and produce less, leading to greater efficiency [32][39]. - The company is focused on both breadth and depth in its partnerships, ensuring high-quality data for specific patient populations [66]. This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Recursion Pharmaceuticals' commitment to innovation, efficiency, and effective partnership management in the biotech industry.

Recursion Pharmaceuticals 2026 Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Date**: March 09, 2026 - **Focus**: Technology-enabled drug discovery, particularly in oncology and immunology Key Points Strategic Focus - Recursion is concentrating on three strategic areas: 1. Doubling down on proof points 2. Surgical investments in the platform 3. Pairing ambition with discipline [1][2][4] Pipeline Management - The company is implementing rapid go/no-go decisions across its programs, emphasizing data-driven decision-making [1][2] - The portfolio is showing increased velocity, synthesizing 90% fewer compounds to reach advanced candidates in about half the time compared to industry standards [2][4] Financial Guidance - For 2026, Recursion expects a gross burn of less than $390 million, excluding inflows from partnerships [6][7] - The company aims to maintain transparency and provide significant updates to annual guidance when necessary [6][7] Partnership Dynamics - Recursion has crossed over half a billion in upfront and milestone payments from partnerships, including significant contributions from Roche and Sanofi [11][12][16] - The Roche partnership focuses on novel targets, with $60 million received in milestones for two datasets [12] - Sanofi's partnership includes five different targets, with potential milestones of $343 million per program [16] Operational Efficiency - The company has reduced pro forma expenses by 35% and is focused on ensuring every dollar contributes to value creation [21][22] - Recursion has made significant investments in its wet and dry lab capabilities, which are crucial for generating high-quality datasets [29][32] Data Strategy - Recursion emphasizes the importance of proprietary data, holding 40 petabytes of data that enhances its drug discovery capabilities [32][54] - The company is actively seeking partnerships to enhance its data assets, focusing on depth and quality of datasets rather than just breadth [53][55] Talent Acquisition - The company faces challenges in recruiting talent proficient in both AI and drug discovery, emphasizing the need for "bilingual talent" [40][41] - Retaining talent involves creating a culture that values both scientific and AI expertise equally [44] Market Positioning - Recursion believes there is ample opportunity in drug discovery, as only about 3% of the genome has an approved drug, indicating a vast untapped market [64][65] - The company aims to leverage its unique data and technology stack to maintain a competitive edge in the industry [62][68] Future Financing - Recursion is exploring various financing options, including partnerships and potential equity or debt instruments, while maintaining a focus on non-dilutive capital [47][49] - The company is positioned to pivot quickly based on pipeline results, which will influence its financing strategy [47][48] Additional Insights - The integration of AI in drug discovery is seen as a critical differentiator for Recursion, allowing for more efficient and effective R&D processes [32][68] - The company is committed to continuous innovation and operational excellence, ensuring that investments are future-facing and aligned with strategic goals [22][29] This summary encapsulates the key discussions and insights from the Recursion Pharmaceuticals conference, highlighting the company's strategic direction, operational efficiencies, and market opportunities.

Core Viewpoint - The article discusses the current state and potential future of Recursion Pharmaceuticals, a healthcare-focused AI company, amidst the growing interest in AI on Wall Street. While some AI stocks have thrived, Recursion has struggled but may have catalysts for improvement in the next 12 to 18 months [1]. Company Overview - Recursion Pharmaceuticals is pioneering the use of AI in drug discovery, testing clinical compounds to predict their likelihood of passing through clinical and regulatory processes. Founded in 2013, the company has seen increased interest in AI from pharmaceutical leaders in recent years [3]. - The U.S. Food and Drug Administration's recent shift away from animal testing towards AI-based models positions Recursion as a potentially forward-thinking player in the biotech space [4]. Current Challenges - Despite its innovative approach, Recursion Pharmaceuticals has not achieved meaningful success, lacking approved products and investigational medicines in late-stage studies [4]. - The company plans to release data from ongoing early-stage clinical trials, primarily focusing on safety and tolerability, which may not significantly impact stock performance even if progress is made [5]. Market Position - Recursion Pharmaceuticals has a market capitalization of $1.8 billion, with a current stock price of $3.46, reflecting a day’s change of -2.40% [6][7]. - The stock has a 52-week range of $2.98 to $7.18, indicating volatility in its market performance [7]. Competitive Landscape - The company aimed to leverage AI for a competitive edge in developing and marketing medicines faster than peers. However, it has not yet launched any medicines, and its competitive advantage is diminishing as more companies adopt similar AI strategies [7]. - Some candidates, like REC-617, show promise in treating various cancers, and partnerships with pharmaceutical giants like Roche and Sanofi may provide easier access to funding [8][9]. Future Outlook - Despite potential strengths, Recursion Pharmaceuticals faces significant clinical and regulatory hurdles to obtain product approvals. Failure to overcome these challenges could lead to further declines in share value, making it a risky investment for risk-averse investors [9].

Core Insights - The presentation is part of TD Cowen's 46th Annual Healthcare Conference, indicating a focus on the healthcare sector and its developments [1]. Group 1 - Recursion's CFO, Ben Taylor, is participating in the conference, suggesting the company's engagement with investors and stakeholders [2]. - The conference aims to discuss various topics related to the healthcare industry, highlighting the importance of communication and information exchange in this sector [2].

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Low Risk Penny Stocks to Buy Now. On February 27, Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) but lowered the price target from $7 to $6. ​The firm said in a research note that the company has yet to prove that its AI‑driven operating system can reliably generate differentiated drug candidates and meaningful patient outcomes. BofA noted that Recursion can do this through repeated wins in cl ...